NIAID Centralized Sequencing Protocol

Primary Immunodeficiency Clinical Trial

Official title:

NIAID Centralized Sequencing Protocol

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03206099
• Other study ID #: 170122
• Secondary ID: 17-I-0122
• Status: Recruiting
• Start date: July 31, 2017
• Est. completion date: December 31, 2029

Study information

• Verified date: May 22, 2024
• Source: National Institutes of Health Clinical Center (CC)
• Contact: Morgan N Similuk
• Phone: (301) 435-6691
• Email: morgan.similuk[@]nih.gov
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Background:

Genetic testing called "sequencing" helps researchers look at DNA. Genes are made of DNA and are the instructions for our bodies to function. We all have thousands of genes. DNA variants are differences in genes between two people. We all have lots of variants. Most are harmless and some cause differences like blue or brown eyes. A few variants can cause health problems.

Objective:

To understand the genetics of immune disorders various health conditions, as well as outcomes of clinical genomics and genetic counseling services performed under this protocol.

Eligibility:

Participants in other NIH human subjects research protocols - either at the NIH Clinical Center (CC) or at Children s National Health System (CNHS) - (aged 0-99 years), and, in select cases, their biological relatives

Design:

Researchers will study participant s DNA extracted from blood, saliva, or another tissue sample, including previously collected samples we may have stored at the NIH. Researchers will look at participant s DNA in great detail. We are looking for differences in the DNA sequence or structure between participants and other people.

Participants will receive results that:

• Are important to their health

• Have been confirmed in a clinical lab

• Suggest that they could be at risk for serious disease that may affect your current or future medical management.

Some genetic information we return to participants may be of uncertain importance.

If genetic test results are unrelated to the participant s NIH evaluations, then we will not typically report:

• Normal variants

• Information about progressive, fatal conditions that have no effective treatment

• Carrier status (conditions you don t have but could pass on)

The samples and data will be saved for future research.

Personal data will be kept as private as possible.

If future studies need new information, participants may be contacted.

Description:

Study Design: This study serves as a centralized sequencing protocol for NIH human subjects research studies to facilitate standardization and consolidate accrual of genotype and phenotype data for participating programs. Participants of other NIH studies both at the NIH CC and CNHS that include genetic testing may enroll in this protocol and genetic testing will be conducted under this

study.

Objective: Primary: To generate and analyze evidence regarding the genetic contribution to diverse immune diseases and other health

conditions studied by the NIH intramural research program (IRP).

Secondary: To generate and analyze evidence regarding the processes and outcomes of the clinical genomics and genetic

counseling services performed under this protocol.

Endpoint: Primary: Discrete genetic contributions to immune diseases and other health conditions, explicitly including:

Established genetic disorders.

Novel genetic defects.

Novel phenotypes associated with established genetic

disorders.

Secondary: Evidence base for how to improve clinical genomic services on this protocol and related programs.

PRECIS

Investigators at the National Institute of Allergy and Infectious Diseases (NIAID) use next-generation sequencing technologies to help determine genetic contributions to immune diseases. These efforts have increased rates of molecular diagnosis for a subset of NIAID

participants as well as uncovered fundamental insights into the cellular and signaling pathways in host defense and immune regulation.

Despite these successes, analysis and interpretation of genomic data remain a substantial challenge. Simply, researchers do not understand the functional and clinical consequences of most human genetic variation. This is true at NIAID and across the intramural research program. Making progress in this area requires a coordinated, systematic, and transparent approach to

clinical genomics research.

This protocol is specific to genetic testing and explicitly aims to both strengthen clinical care and enhance research throughout participating programs at the NIH. Probands will provide biological specimens for genetic testing and will be required to be enrolled on a primary protocol, which will execute the primary clinical and research evaluations. This protocol serves as a vehicle for a

programmatic effort that includes standardized phenotyping, test ordering through the Clinical Research Information System (CRIS), sample collection and isolation, nucleic acid analysis, bioinformatics, clinical interpretation, reporting in CRIS, genetic counseling, and supporting effective use of genomics as a research tool throughout the intramural program. Genetic testing results and data (upon request) will be shared with the research teams for protocols on which a given participant is co-enrolled. Overall, increased process standardization will support data integrity and efficiency while still accommodating the need for investigator flexibility.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10000
• Est. completion date: December 31, 2029
• Est. primary completion date: December 31, 2029
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 1 Day and older

Eligibility

• PARTICIPANT INCLUSION CRITERIA:

• Must fulfill one of the following criteria:

• Proband participants: must have a disease under investigation by another NIH protocol on which they are co-enrolled.

• Biological relatives: biologically related to a proband participant, and does not have a disease under investigation in another NIH protocol.

• Healthy volunteers: unrelated to a proband participant, and does not have a disease under investigation in another NIH protocol.

• Aged 0-99 years.

• Participants must be willing to undergo genetic testing.

• Participants must be willing to allow samples to be stored for future research.

• Participants must be willing to have their de-identified genomic data shared, for example in a controlled access databases like the Database of Genotypes and Phenotypes (dbGaP).

• Adult healthy volunteers must be able to provide informed consent.

PARTICIPANT EXCLUSION CRITERIA:

Any condition that, in the opinion of the investigator, contraindicates participation in this study is a reason for exclusion.

Co-enrollment guidelines:

Probands must be enrolled on another NIH - either at the NIH CC or CNHS - protocol as their primary protocol for carrying out clinical and research evaluations. Relatives of probands may be enrolled in this protocol whether or not the relatives are enrolled on another NIH protocol. However, we may prioritize enrolling relatives who are on other NIH protocols and have undergone careful phenotyping on those protocols. Careful phenotyping is important, even for participants who are apparently healthy. Because the primary research team is best suited to characterize their participants phenotypes, phenotyping of co-enrolled relatives will be performed on the primary protocols.

SUBSTUDY INCLUSION CRITERIA:

• Aged 14-99 years.

• English language proficiency.

• Ability to provide informed consent.

SUBSTUDY EXCLUSION CRITERIA:

• Have received positive genetic results from this protocol in the past.

• Any condition that, in the opinion of the investigator, contraindicates participation in this substudy.

Related Conditions & MeSH terms

• Atopy
• Autoimmunity
• Autoinflammation
• Primary Immunodeficiency
• Primary Immunodeficiency Diseases

Locations

Country	Name	City	State
United States	National Institutes of Health Clinical Center	Bethesda	Maryland
United States	Children's National Health System	Washington	District of Columbia

Sponsors (2)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)	National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Identifying novel genetic defects associated with immune disorders	Identifying novel genetic defects associated with immune disorders	Upon analysis of genomic data
Primary	Identifying novel clinical phenotypes associated with established genetic defects	Identifying novel clinical phenotypes associated with established genetic defects	Upon analysis of genomic data
Primary	Identifying established genetic disorders of the immune system	Identifying established genetic disorders of the immune system, as well as known genetic disorders outside of the immune system in some cases	Upon analysis of genomic data
Secondary	Evidence base for how to improve clinical genomic services on this protocol and related programs.	Studies of the processes and outcomes of the clinical genomics and genetic counseling services performed under this protocol. These studies will use surveys, interviews, and other social and behavioral research methods to collect data from study participants about their perceptions, experiences, and attitudes related to their condition and participation in this protocol. The goal of these additional studies will be to improve the services provided under protocol 17-I-0122 and to generate an evidence base for other investigators conducting similar studies.	5.1.1. Enrollment/Baseline Report Comprehension Survey and Semi-Structured Phone Interviews

External Links

•   NIH Clinical Center Detailed Web Page